Background: Patients undergoing laparoscopic gynecological surgery have a remarkably high incidence of postoperative nausea and vomiting (PONV). The purpose of this study was to evaluate the effect of the timing of ramosetron administration on its antiemetic efficacy in patients undergoing laparoscopic gynecological surgery.
Methods: One hundred and twenty patients undergoing laparoscopic gynecological surgery under general anesthesia were randomized to receive 0.3 mg of ramosetron intravenously either immediately after induction (group I, n = 60) or at the completion of surgery (group II, n = 60). Occurrences of nausea and vomiting, the need for rescue antiemetics and analgesics, pain score, as well as adverse events associated with study medications, were recorded for 48 hrs after the operation.
Results: The incidence of postoperative nausea and vomiting in the I and II groups were 46.7%, 41.7% respectively. There was no significant difference between the groups in the incidences of PONV, the need for rescue antiemetics and analgesics, pain score and adverse events associated with study medications (P > 0.05).
Conclusions: The effect of ramosetron administered either immediately after induction or at the completion of surgery was similar to each other on its efficacy as a prophylactic antiemetic in patients undergoing laparoscopic gynecological surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4097/kjae.2009.56.6.663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Recruitment Method on Clinical Outcomes Following Cervical Disc Arthroplasty.
Spine (Phila Pa 1976)
January 2025
Indiana Spine Group Location of investigation Indiana Spine Group, 13225 N. Meridian Street, Carmel, IN 46032.
Study Design: Retrospective cohort.
Objective: To compare the clinical outcomes of trial versus standard clinical practice (SCP) patients following cervical disc arthroplasty (CDA).
Background: CDA is hypothesized to reduce the shear strain and related complications resulting from fusion procedures.
Increased SCUBE-1 levels in the aqueous humour of patients with pseudoexfoliation syndrome.
Clin Exp Optom
January 2025
Department of Ophthalmology, Dünyagöz Tunus Hospital, Ankara, Türkiye.
Clinical Relevance: Pseudoexfoliation syndrome (PXS) is a common age-related disorder associated with glaucoma and cataract. Despite its clinical importance, the pathogenesis of PXS is not yet fully understood.
Background: To evaluate levels of SCUBE-1 (signal peptide, CUB domain, and epidermal growth factor-like domain containing protein 1) in the serum and aqueous humour of patients with PXS in comparison with non-PXS controls.
Background And Aims: A catheter-related bloodstream infection (CRBSI) is a life-threatening complication of hemodialysis. It is responsible for significant morbidity and mortality and a costly long hospital stay. Despite its burden, little is known about the factors associated with it and the antibiogram of its responsible causative bacteria.
View Article and Find Full Text PDFPredictive Clinical Factors of Pain-Related Quality of Recovery Following Elective Gastrointestinal and Hepato-Pancreato-Biliary Surgery: An Observational Study in Norway.
J Pain Res
January 2025
Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Purpose: This observational cohort study aimed to identify predictive factors associated with pain-related quality of recovery among patients undergoing elective gastrointestinal and hepato-pancreato-biliary surgery.
Patients And Methods: This study involved a secondary analysis of the data collected from five hospitals across all healthcare regions in Norway to validate the Norwegian version of the Quality of Recovery-15 (QoR-15NO). The sample consisted of 268 adult patients who underwent elective gastrointestinal and hepato-pancreato-biliary surgery between September 2021 and May 2022.
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.
J Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!